66.86

1.20% +0.79

After Hours: 66.86

Nuvalent Inc (NUVL)

Overview News Price History Option Chain Why NUVL Down? Discussions Forecast

Nuvalent Inc stock is currently priced at $66.86, with a 24-hour trading volume of 227.76K. It has seen a +1.20% increased in the last 24 hours and a -11.72% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $65.68 pivot point. If it approaches the $66.92 resistance level, significant changes may occur.

Previous Close:

$66.07

Open:

$66.23

24h Volume:

227.76K

Market Cap:

$4.28B

Revenue:

Net Income/Loss:

$-126.22M

P/E Ratio:

-36.14

EPS:

-1.85

Net Cash Flow:

$-99.74M

1W Performance:

+6.53%

1M Performance:

-11.72%

6M Performance:

+23.93%

1Y Performance:

+90.16%

1D Range:

$65.08

$66.89

52W Range:

$33.03

$89.39

Nuvalent Inc Stock (NUVL) Company Profile

Name

Nuvalent Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

857-357-7000

Address

One Broadway, 14th Floor, Cambridge

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NUVL's Discussions on Twitter

Nuvalent Inc Stock (NUVL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-28-24	Resumed	Guggenheim	Buy
Feb-23-24	Initiated	Robert W. Baird	Outperform
Sep-27-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-24-23	Initiated	Guggenheim	Buy
Jan-18-23	Initiated	Wedbush	Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform

View All

Nuvalent Inc Stock (NUVL) Financials Data

Nuvalent Inc (NUVL) Net Income 2024

NUVL net income (TTM) was -$126.22 million for the quarter ending December 31, 2023, a -54.20% decrease year-over-year.

Nuvalent Inc (NUVL) Cash Flow 2024

NUVL recorded a free cash flow (TTM) of -$99.74 million for the quarter ending December 31, 2023, a -53.51% decrease year-over-year.

Nuvalent Inc (NUVL) Earnings per Share 2024

NUVL earnings per share (TTM) was -$2.16 for the quarter ending December 31, 2023, a -31.71% decline year-over-year.

Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.